Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity

Nature Medicine

Volumn 7, Issue 8, 2001, Pages 954-960

  Ichikawa, Kimihisa ^a   Liu, Weimin ^b   Zhao, Limin ^b   Wang, Zheng ^b   Liu, Di ^b   Ohtsuka, Toshiaki ^a   Zhang, Huangge ^b   Mountz, John D ^b   Koopman, William J ^b   Kimberly, Robert P ^b   Zhou, Tong ^b  

^a DAIICHI SANKYO CO   (Japan)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDOMA; LIVER CANCER; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; BRAIN NEOPLASMS; DNA PRIMERS; FEMALE; GLIOMA; HEPATOCYTES; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17944376030     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/91000     Document Type: Article

References (26)

1. Identification and characterization of a new member of the TNF family that induces apoptosis
2. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
3. Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo
4. Safety and antitumor activity of recombinant soluble Apo2 ligand
5. The receptor for the cytotoxic ligand TRAIL
6. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
7. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway
8. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
9. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
10. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family
11. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
12. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
13. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2- mediated cell death but not gene induction
14. TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells
15. TRAIL receptor-2 signals apoptosis through FADD and caspase-8
16. FADD is required for DR4- and DR5-mediated apoptosis: Lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts
17. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2
18. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5
19. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways
20. TRAIL induces apoptosis and activation of NF-κB
21. JNK/SAPK activity contributes to TRAIL-induced apoptosis
22. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
23. Apoptosis induced in normal human hepatocytes by tumor necrosis factor- related apoptosis-inducing ligand
24. Functional analysis of TRAIL receptors using monoclonal antibodies
25. Antitumor activity and bystander effects of the tumor necrosis factor- related apoptosis-inducing ligand (TRAIL) gene
26. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions